SCHEMBL1006162

SCHEMBL1006162

Oc1ccccc1-c1ccc2ccc3cccnc3c2n1.[LiH]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
MMP2 P08253 2/20 0.55
CHRM1 P11229 1/20 0.55
COMT P21964 1/20 0.55
ADRA1A P35348 1/20 0.55
METAP2 P50579 1/20 0.55
METAP1 P53582 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
KDM4E B2RXH2 6/20 0.53
TDP1 Q9NUW8 4/20 0.53
LMNA P02545 3/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
CCR1 P32246 3/20 0.53
CCR5 P51681 3/20 0.53
CCR8 P51685 3/20 0.53
TP53 P04637 2/20 0.53
ALOX15 P16050 2/20 0.53
HTT P42858 2/20 0.53
NFKB1 P19838 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85419 0.98 TSHR (0.56) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL10299988 0.89 TSHR (0.50) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL57699 0.88 IDO1 (0.46) TDP1LMNAMAPTSMN1; SMN2TP53
SCHEMBL19831083 0.86 MMP2 (0.47) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL30835076 0.86 MMP2 (0.47) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL30835135 0.86 MMP2 (0.47) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL28609444 0.85 MMP2 (0.46) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL14900783 0.84 LMNA (0.64) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL12853992 0.84 LMNA (0.64) TSHRMMP2CHRM1COMTADRA1A
SCHEMBL17146643 0.83 KDM4E (0.57) TSHRMMP2CHRM1COMTADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2232612-B1 OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS GLOBAL OLED TECHNOLOGY LLC (US) 2017-02-08 EP disclosed
US-8900722-B2 OLED device employing alkali metal cluster compounds GLOBAL OLED TECHNOLOGY LLC (US) 2014-12-02 US disclosed
US-8877356-B2 OLED device with stabilized yellow light-emitting layer GLOBAL OLED TECHNOLOGY LLC (US) 2014-11-04 US disclosed
EP-2456617-B1 OLED DEVICE WITH STABILIZED YELLOW LIGHT-EMITTING LAYER GLOBAL OLED TECHNOLOGY LLC (US) 2014-07-02 EP disclosed
CN-101878554-B Oled device employing alkali metal cluster compounds GLOBAL OLED TECHNOLOGY LLC 2012-07-25 CN disclosed
EP-2456617-A1 OLED DEVICE WITH STABILIZED YELLOW LIGHT-EMITTING LAYER Global OLED Technology LLC (US) 2012-05-30 EP disclosed
WO-2011011501-A1 OLED DEVICE WITH STABILIZED YELLOW LIGHT-EMITTING LAYER GLOBAL OLED TECHNOLOGY LLC (US) 2011-01-27 WO disclosed
US-20110018429-A1 OLED DEVICE WITH STABILIZED YELLOW LIGHT-EMITTING LAYER GLOBAL OLED TECHNOLOGY LLC 2011-01-27 US disclosed
CN-101878554-A Oled device employing alkali metal cluster compounds EASTMAN KODAK CO 2010-11-03 CN disclosed
EP-2232612-A1 OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS Global OLED Technology LLC (US) 2010-09-29 EP disclosed
WO-2009073088-A1 OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS EASTMAN KODAK COMPANY (US) 2009-06-11 WO disclosed
US-20090142618-A1 OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS GLOBAL OLED TECHNOLOGY LLC 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090142618-A1 OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS OCIAD2, OCIAD1, OSTC TSHR 4338/4885MMP2 4104/4885CHRM1 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.